With the consent of Isofol, Endo Ventures has designated Paladin Labs Inc., an operating company of Endo, to be responsible for seeking regulatory approval for arfolitixorin in Canada and after receipt of such approval, to be responsible for the commercialization of arfolitixorin in Canada, including distribution, marketing, medical affairs, pricing and reimbursement activities. Isofol may receive up to US $ 23.05 million (SEK 205 million**) as upfront, development, regulatory, and sales-based milestone payments. In addition, Isofol will receive tiered royalties on net sales in solid double-digit figures.